Leerink Partnrs boosted their FY2024 EPS estimates for shares of Beigene in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to ...

The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...

ImmunityBio has entered a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...